9. Corcept Therapeutics (CORT)
Company Profile: Corcept Therapeutics is a biopharmaceutical company developing Corlux, a synthetic steroid to treat Cushing's syndrome.Share Price: $4.22 (March 29) Stock Performance This Year: 9% Analyst Consensus: Seven Wall Street firms rate Corcept a "buy," including Stifel Nicolaus and Piper Jaffray. Only one analyst says investors should dump shares. The average price target of $6.60 implies potential upside of 56%. Bullish Case: McNicoll Lewis Vlak analyst Christopher James initiated coverage of Corcept on March 10 with a "buy" rating and $8.50 price target. "Given the interviews conducted with both endocrinologists and practicing neurosurgeons, we feel uniquely positioned in the understanding of Cushing's syndrome, and the approvability and potential market size for Corlux," James wrote in his research note, adding that he has a high level of confidence that Corlux will be approved in early 2012. TheStreet Ratings doesn't have a rating on Corcept Therapeutics.